The JCO Podcast hosted by Dr. Shannon Westin features discussions of new and noteworthy results publ
This Podcast reviews the background of the MA.17 trial, the results of the present manuscript and pr
This podcast summarizes the findings of this JCO article and provides commentary on its applicabilit
This podcast will critically review randomized phase III trial data examining the relative role of t
This podcast discusses findings and implications of a recent survey study on attitudes and knowledge
This podcast will explore the feasibility of a nonoperative "wait and see" approach based on strict
This podcast reviews the evidence that women testing negative for known familial BRCA1/2 mutations s
This Podcast provides observation and commentary on the JCO article "Sequential versus concurrent tr
Podcast to review the article "Occult Metastases in Length Nodes Predict Survival In Resectable Non-
The ATAC investigators collected comorbidity data on more than 9000 women and this article illustrat
Rapid, dramatic shifts are ongoing in the population-level epidemiology of oropharynx cancer in the
EGFR mutation is a predictive biomarker for maintenance erlotinib but its clinical application is li
This podcast summarizes the incidence and long-term outcome of osteonecrosis in a large prospective
This podcast evaluates the context and reviews results of a randomized phase III trial comparing R-C
This podcast reviews the randomized double-blind placebo-controlled trial reported by Boekhout et al
This podcast reviews the retrospective study by Arun et al. and discusses the lack of consensus rega
Androgen deprivation therapy may not be associated with an increase in cardiovascular mortality in a
Stage II colon cancer with high risk factors is often treated with adjuvant therapy, however new dat
Commentary on a successful study in which genotype-guided tamoxifen dosing increased endoxifen conce
Estrogen plus progestin and estrogen alone have different effects on mammographic density and breast
This is a commentary on a recent study comparing two risk calculators for use in the setting of pros
